Standard BioTools (LAB) Fundamentals 2026 — Revenue Analysis | SniperIQ
Standard BioTools (LAB) is a US-listed Healthcare company in Medical - Equipment & Services with a market capitalization of
Standard BioTools (LAB) has a market capitalization of approximately
Standard BioTools's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Standard BioTools runs a net profit margin of -109.1%, a gross margin of 48.3%, and an operating margin of -91.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Standard BioTools reported revenue of $85M for fiscal year 2025, with net income of -$75M and earnings per share (EPS) of -0.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Standard BioTools does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Standard BioTools carries a debt-to-equity ratio of 0.05x and a current ratio of 12.36x, with a market beta of 1.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Standard BioTools (LAB) the key facts are: market cap
Get Standard BioTools's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.